Management of Persistent Hypotony after Supraciliary CyPass^® Implantation Using Argon Laser.

ABSTRACT:

Purpose

To report a case and management of persistent hypotony with hypotony-induced maculopathy after CyPass^® device implant.

Background

The CyPass^® was the first supraciliary ab interno device approved by FDA and commercially available. Efficacy studies showed adequate intraocular pressure (IOP)-lowering results in combination with phacoemulsification. Hypotony induced by suprachoroidal minimally invasive glaucoma surgery (MIGS) was reported to be lower than 3% in the population that comprised the COMPASS study.

Case description

A 57-year-old female patient with mild open-angle glaucoma with maximum topical medical therapy who underwent sequential bilateral CyPass^® implantation developed persistent hypotony. Device obstruction

SUBMITTER: Fernando DV 

PROVIDER: S-EPMC7221243 | biostudies-literature | 2019 Sep-Dec

REPOSITORIES: biostudies-literature